SCHEMBL3974247

SCHEMBL3974247

Cc1ccc(C)c(-n2nc(C(C)(C)C)cc2Nc2ncccc2C(N)=O)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
MAPT P10636 2/20 0.52
AHR P35869 1/20 0.52
MAPK14 Q16539 12/20 0.47
MAPK13 O15264 5/20 0.47
MAPK12 P53778 5/20 0.47
MAPK11 Q15759 5/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
CDK8 P49336 1/20 0.44
MAPK9 P45984 3/20 0.42
DDR2 Q16832 2/20 0.42
LMNA P02545 1/20 0.42
MAP4K2 Q12851 1/20 0.41
PTK2 Q05397 1/20 0.41
BRAF P15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979286 0.92 LMNA (0.51) RAB9ANPC1MAPTMAPK14MAPK13
SCHEMBL3978596 0.91 LMNA (0.49) RAB9ASMN1; SMN2NPC1MAPTAHR
SCHEMBL3980152 0.91 MAPK14 (0.56) RAB9ASMN1; SMN2NPC1MAPTAHR
SCHEMBL3974469 0.90 MAPK14 (0.46) RAB9ASMN1; SMN2NPC1MAPTAHR
SCHEMBL3972985 0.89 MAPK14 (0.45) RAB9ASMN1; SMN2NPC1MAPTAHR
SCHEMBL3974140 0.84 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11CDK8
SCHEMBL3975609 0.84 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTMAPK14MAPK13
SCHEMBL4084990 0.84 MAPK14 (0.43) NPC1MAPK14MAPK13MAPK12MAPK11
SCHEMBL3864506 0.83 MAPK14 (0.48) RAB9ANPC1MAPTMAPK14MAPK13
SCHEMBL3979999 0.83 RAB9A (0.47) RAB9ASMN1; SMN2NPC1MAPTAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP RAB9A 2873/4885SMN1; SMN2 4413/4885NPC1 303/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP RAB9A 2873/4885SMN1; SMN2 4413/4885NPC1 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.